VLA1553
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chikungunya
Conditions
Chikungunya
Trial Timeline
Mar 5, 2018 → Jul 28, 2019
NCT ID
NCT03382964About VLA1553
VLA1553 is a phase 1 stage product being developed by Valneva SE for Chikungunya. The current trial status is completed. This product is registered under clinical trial identifier NCT03382964. Target conditions include Chikungunya.
What happened to similar drugs?
0 of 11 similar drugs in Chikungunya were approved
Approved (0) Terminated (2) Active (9)
Hype Score Breakdown
Clinical
6
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06028841 | Phase 3 | Withdrawn |
| NCT04838444 | Phase 3 | Active |
| NCT03382964 | Phase 1 | Completed |
Competing Products
20 competing products in Chikungunya